Relapsed indolent lymphoma often becomes refractory to standard chemoimmunotherapy and requires new therapeutic strategies. Targeting the PI3K/mTOR pathway in several types of lymphoma has shown preclinical and clinical efficacy providing the rationale to test this strategy in the treatment of relapsed/refractory indolent lymphomas. We investigated in a phase II open label clinical trial the efficacy and safety of single agent everolimus, an inhibitor of mTORC1, in patients with relapsed/refractory indolent lymphomas. Eligible patients received oral everolimus 10 mg daily on a 28 day-cycle schedule. The primary endpoint was to evaluate the overall response rate (ORR) and safety of single-agent everolimus in this patient population. Fifty-five patients with indolent lymphoma were accrued. The median age was 67 years (range: 33-85) with a median of five prior therapies (range: 1-10). The ORR was 35% (19/55; 95% CI: 24-48%), with complete response unconfirmed in 4% (2/55), and partial response in 31% (17/55). The ORR was 61% (14/ 23) in the patients with FL. The median time to response was 2.3 months (range: 1.4-14.1), median duration of response of 11.5 months (95%-CI: 5.7-30.4), and a median progression-free survival of 7.2 months (95%-CI: 5.5-12.5). The most common toxicity was hematologic with grades 3-4 anemia, neutropenia, and thrombocytopenia documented in 15% (8/55), 22% (12/55), and 33% (18/ 55), respectively. There were no cases of febrile neutropenia, and eight patients discontinued therapy because of adverse events. Everolimus monotherapy is a valid therapeutic option in the relapsed and/or refractory indolent non-Hodgkin lymphoma patients and is well tolerated. relapse within 2 years of initial therapy. When studied, patients with early progression after chemoimmunotherapy (ie, less than 24 months after initial therapy) had a significantly worse prognosis than those with a later relapse, with a 5-year overall survival (OS) of 50% versus 90%. 4 Furthermore, in another study, FL patients with events (ie, progression, relapse, or retreatment) occurring during the first 12 months of diagnosis had significantly worse overall outcomes compared to those who were event-free at 12 months. 5 During a relapsing remitting This trial was registered at www.clinicaltrials.gov as #NCT00436618.
course, iNHL become refractory to standard chemoimmunotherapy combinations. Having multiple therapeutic options in the relapsed setting is necessary, and accordingly, several new therapeutic targets have been explored.
Targeting the mammalian target of rapamycin (mTOR) has recently been the focus of preclinical and clinical studies as activation of the PI3K/Akt/mTOR pathway is a major driver of B-cell growth and survival. 6 Accordingly, deregulations in this pathway were shown to play a key role in many solid and hematologic malignancies. [7] [8] [9] [10] Temsirolimus and everolimus, inhibitors of mTORC1, are both FDA approved for the treatment of renal cell carcinoma and temsirolimus is approved for relapsed mantle cell lymphoma in Europe. We have previously reported in vitro 10, 11 and in vivo 8, 9, 11 that everolimus is active against various relapsed NHL subtypes, as well as relapsed Hodgkin lymphoma (HL). 9 The median overall response rates (ORR) varied from 30% in DLBCL and mantle cell lymphoma (MCL) 11 to 50% in Waldenstr€ om macroglobulinemia, with a clinical benefit rate of 73% when minimal responses were included in the latter cohort. 8, 12 In a phase I study conducted in Japanese patients, a total of five patients with FL were treated with single agent everolimus. One patient received 5 mg per day and four patients received 10 mg per day. Two of the five patients responded with a duration of response of 113, and 24 days, respectively. 13 Temsirolimus, another rapalog, administered intravenously, was studied in relapsed/refractory FL with a reported ORR of 53%. 14 Based on preclinical and phase I/II data and safety profile, we investigated in a phase II clinical trial the efficacy and safety of single agent everolimus in patients with relapsed/refractory iNHL.
| P A T I E NT S A ND M E T H O DS
MC048G was a phase II study conducted prospectively to assess response rates to single-agent everolimus in patients with various types of relapsed and/or refractory lymphoma. The study accrued a total of 277 patients to three cohorts of patients with relapsed lymphomaaggressive NHL, indolent NHL and uncommon NHL. This report concerns the cohort of patients with indolent NHL. The primary endpoint was to evaluate ORR. The secondary endpoints were safety of everolimus, OS, progression free survival (PFS) and duration of response (DR) in the same population. The study was approved by the Mayo Clinic and Dana Farber Institutional Review Board, and all patients provided written informed consent.
Eligibility criteria included iNHL that was biopsy proven within 6 months of enrollment. Response was assessed after two and six cycles, and every three cycles thereafter. Responses were recorded according to the International Workshop Criteria for lymphoma. 15 In patients with complete response after six cycles, two additional cycles were administered, and treatment could be stopped or continued at treating physician and patient discretion. Patients with PR were continued until progression or unacceptable toxicities. In the case of stable disease after six cycles, treatment could be continued at physician discretion.
| Statistical design
This phase II study used a two-stage Simon optimum design 16 to assess the efficacy and tolerability of everolimus in patients with iNHL. The ORR was estimated by the number of responses divided by the number of evaluable patients. A total of 37 evaluable patients were required to test the null hypothesis that the true ORR for this regimen is at most 20% versus the alternative hypothesis that the true ORR is 40% or greater. The study had 90% power, with a 9% type I error rate. An additional 18 patients were accrued to this cohort -4 patients to account for ineligibility and cancellations and 14 patients as part of a compassionate use expansion that allowed access to everolimus before the study was completed. Therefore, a total of 55 patients with iNHL are included in this report. Confidence intervals for the true success proportion were calculated according to the approach of Duffy and Santner. 17 A response was defined as a CR, CRu, CCR, nPR, or PR at any time. All patients meeting the eligibility criteria who provided informed consent and received at least one dose of treatment were considered evaluable for response. DR was defined as the time from the date of first documented response to the date of disease progression. PFS was defined as the time from registration to the date of disease progression or death from any cause. OS was defined as the time from registration to death from any cause. The distributions of these time-to-event end points were estimated using the Kaplan-Meier method. 18 Toxicity was defined as an adverse event classified as being possibly, probably, or definitely related to study treatment. 
| R E S U L T S 3.1 | Patient characteristics

| DISCUSSION
The treatment of relapsed iNHL requires thoughtful management given the risk for toxicity and the potential for multiple lines of previous therapies. The iNHL patients entered in this study were a typical group of relapsed iNHL with a median of five prior therapies. Despite the heavily pretreated nature of the patients in this trial, we have demonstrated that monotherapy with the oral mTORC1 inhibitor everolimus is active in patients with relapsed and/or refractory iNHL with an ORR of 35%, a median PFS of 7.2 months, a median OS of 29.4 months, and a median duration of response of 11.5 months. Of note, the ORR in the 1st 37 evaluable patients was 10/37 (27%, 95% CI: 16, 45), which did not meet the success criteria prespecified by the statistical design.
However, these outcomes were encouraging in the FL subgroup (61%) and clinically relevant given this is an oral agent and the study population was relapsed or refractory. observations for everolimus might be a general property of rapalogs.
Our previous results of everolimus in relapsed aggressive NHL included 8 patients with FL-grade III and 38% (3/8) responded.
11
Targeting the PI3K/mTOR signaling pathway at the level of PI3K itself has also been demonstrated to be effective in NHL. Indeed, the PI3Kᵟ inhibitor idelalisib has demonstrated an ORR of 54% in FL patients who had failed two prior therapies and was approved by the US FDA in this setting. The median PFS was 11 months for all subgroups combined. 25 Idelalisib, due to higher ORR and CR rate, will likely be used prior to everolimus in the relapsed setting in iNHL. There are no data regarding the responsiveness to everolimus in patients who have failed idelalisib. Due to higher rates of side effects observed in phase III trials, a black box warning for fatal and/or severe diarrhea or colitis, intestinal perforation, hepatotoxicity, and pneumonitis is listed in the US prescribing information for idelalisib. 26 Everolimus also has a black box warning regarding its use in transplant patients and also has a risk of noninfectious pneumonitis but is less likely to have the gastrointestinal and hepatic toxicities observed with PI3K inhibitors.
The optimal use of everolimus in iNHL is likely to be in combination with other agents. The rationale behind some of the combinations being currently tested is based on preclinical data. We have reported in NHL cell lines in vitro that despite inhibition of mTORC1, mTORC2 is activated through Akt, thus allowing for emergence of resistance to the mTORC inhibitor. 27 Combination therapy with the histone deacetylase inhibitor panobinostat overcame this mechanism of resistance in vitro.
Panobinostat has been combined with everolimus in a phase I trial in (1) relapsed/refractory lymphoma that included two FL cases. 28 The combination was safe with some antitumor activity providing proof of concept for further studies. In combination with rituximab, everolimus led to a 38% ORR in relapsed DLBCL. 29 In a phase I study of untreated DLBCL, everolimus was combined with RCHOP chemotherapy in a frontline setting. 30 Everolimus administered at 10 mg days 1 to 14 of each cycle of RCHOP-21 was well tolerated and was associated with a 96% CR rate in both germinal center B-cell and activated-B cell DLBCL in combination with R-CHOP. Similarly, a study of combination therapy with a CHOP-21 regimen in newly diagnosed peripheral T-cell lymphomas at a dose of 5 mg days 1 to 14 was reported to be safe. 31 In this study, everolimus was well-tolerated with modest hematologic toxicity. The grade 3-4 neutropenia in 22% of the patients is similar to the 27% of patients treated with the PI3K inhibitor idelalisib 25 and less than the 54% of patients treated with single agent bendamustine. 32 Grade 3-4 thrombocytopenia was observed in 33%, similar to single agent bendamustine (25%). 
